HUM Stock Analysis — Humana
Sector: Healthcare
AI Verdict
You're paying up for a 41.4% earnings growth story at 30.0x forward P/E, so unless Humana's care management moat delivers, there's little margin for error at these levels.
Competitive Moat
Humana operates Medicare Advantage and other health insurance plans, leveraging scale in senior-focused care management and deep provider relationships to lock in recurring government-backed revenue streams. Its defensibility comes from regulatory complexity and high switching costs for seniors, making it hard for new entrants to displace their membership base.
Summary
Humana is in focus as its forward P/E of 30.0x and projected 41.4% EPS growth signal a sharp earnings rebound after a tough year.
Where It Stands
Humana is up 66.87% over the past year, trades at 30.0x forward earnings (vs. the healthcare sector median of 22x), and its RSI of 66.6 signals elevated pullback risk.
Key Metrics
- RSI: 66.6 — Near Overbought
- Trailing P/E: 42.4x
- Forward P/E: 30.0x
- PEG Ratio: 1.03
- Earnings Growth: +0.4%
- Revenue Growth: +0.1%
- Market Cap: $47.6B
- Dividend Yield: 0.01%
- 1-Year Return: 66.87%
- 52-Week High: $415.00
- 52-Week Low: $163.11
Analyst Consensus
11 Buy · 20 Hold · 2 Sell (33 analysts)
Bull Case
With analysts forecasting 41.4% EPS growth and a forward P/E of 30.0x, you're paying a fair multiple for a sharp earnings recovery if Humana's care management moat holds.
Bear Case
If the multiple compresses from 30.0x to the sector median of 22x, shares could drop over 25% even if earnings hit targets, especially with an RSI of 66.6 suggesting technical overextension.
Catalyst to Watch
Watch for quarterly EPS guidance updates — upside revisions could justify the premium, while any disappointment risks a sharp derating.